BE693874A - - Google Patents

Info

Publication number
BE693874A
BE693874A BE693874DA BE693874A BE 693874 A BE693874 A BE 693874A BE 693874D A BE693874D A BE 693874DA BE 693874 A BE693874 A BE 693874A
Authority
BE
Belgium
Prior art keywords
sep
bis
hydroxyphenyl
bia
methane
Prior art date
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BE693874A publication Critical patent/BE693874A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

  

   <Desc/Clms Page number 1> 
 
 EMI1.1 
 



  Sels d'addition stables du bis.(4-hydroxyphny.- (quinolylJ-2)méthane avec des acides 
L'invention est relative à des sels d'addition stables du   bis-(4-hydroxyphényl)-(quinolyl-2)-méthane   avec des acides . 
 EMI1.2 
 le brevet Allemagne nO ,.0$7.011 décrit entre autres la fabrication de bia-(4"hydroxyphenyl)-(quinolyl<2)-méthane      de formule ; 
 EMI1.3 
 par la réaction entre le   quinolyl-1-aldéhyde   et le phénol ; ce composé a un effet laxatif remarquable et une toxicité très atténuée, 

 <Desc/Clms Page number 2> 

 
 EMI2.1 
 Il est toutefois apparu que le b.s-(4hYdroxyphëny.). 



    (quinolyl-2)-méthane,   qui, fraîchement préparé, se présente sous la forme d'une substance incolore, se colore lors d'un stockage prolongé par suite d'une lente modification de la molécule. Cette coloration se produit rapidement lors du traitement avec des solvants polaires tels que, par exemple, des mélanges   d'éthanol   et d'eau du genre de ceux   qu'on   applique par exemple pour la granulation préalable à la formation de tablettes par compression, ce qui constitue un grave inconvénient pour la fabrication de préparations pharmaceutiques. 



   On vient de découvrir maintenant, d'une façon inat- tendue- qu'on peut éviter ces inconvénients, lorsqu'on 
 EMI2.2 
 convertit le bis-(4-hydroxyphényl)-(quinolyl-2)-méthane ou 
 EMI2.3 
 en ses sels d'addition avec des acides min6raux/organiquei3 forts physiologiquement supportables. De plus, ces sels se distinguent par une excellente tolérance gastrique. Comme acides minéraux, on peut citer de préférence les adices chlorhydrique, bromhydrique,sulfurique et phosphorique, 
 EMI2.4 
 r3c4mms acides organiques forts, les acides méthanesulfonique, p. to.uneau,fonâ.que et benzéne-sulfonique, La conversion du b. s .

   ( ...hYdraxynnnyx ) -( quirolyl-2 j méthane en ses sels d'addition avec des acides physiologie   quement   supportablesa avantageusement lieu dans un solvant   inerte*   Les solvants entrant surtout en ligne de compte sont, par exemple, des cétones telles que l'acétone, ou des alcools comme,par exemple, le méthanol ou   l'éthanol,   
 EMI2.5 
 Les sels du bis.  ( ,. hydroxyphnyl ).. ( quinel 1...2 .. méthane se distinguent par une excellente tolérance et un effet laxatif remarquable, Ainsi, le chlorhydrate de bis- 

 <Desc/Clms Page number 3> 

 
 EMI3.1 
 (4-hYdrïoxYPhênYl)-(quinolYI-2)-méthane exerce son effet laxatif sur l'homme déjà à une dose de 30 mg. 



   On peut fabriquer, à partir de ces sels, des pré- parafions pharmaceutiques stables telles que des comprimés, des suppositoires et des suspensions. Etant donné que les 
 EMI3.2 
 sels du bis-(@-hydroXyphényl)-(quinolyl-2)-méthanoe Jouis- sent d'une très bonne tolérance gastrique, la dragéification des comprimés contenant ces sels devient inutile. Le dosage pour adultes est compris entre 30 et 250   mg.   



   Les exemples ci-dessous servent à illustrer l'in- vention plus en détail, EXEMPLE   1,,..   Préparation du chlorhydrate de bis-(4-hydroxy- 
 EMI3.3 
 phényl)-(quinolyl-2)-méthane , On met 40g de bis-(Y-hydroxyphénylJ-(quinolyl-2)- méthane en suspension dans 200 ml d'acétone. On introduit dans ce mélange du gaz chlorhydrique jusqu'à   saturation,   en agitant et refroidissant. On essore la masse cristal- line d'un jaune clair et on la sèche. On obtient 39g de chlorhydrate de P.F, 205 C. 
 EMI3.4 
 



  Bn faisant réagir le bis-(4-hydroxyphényl)-(quiolYl- 2)-méthane dans l'acétone ou dans l'éthanol avec les acides correspondants, on obtient les sels ci-dessous 
 EMI3.5 
 a) le sulfate acide Paf'. 238*r, b) le méthane8ulfonate P.F. 224*0 et) le toluéne-sulfonate P.F, 136 0 d) le benzéne-sulfonate P.F. 1)8 C su le bromhydrate , F, 21,800 le phosphate acide Bzz. 22600 

 <Desc/Clms Page number 4> 

 
Ci-après on donne,à titre   d'exemple,   la   composi-   tion de   quelques     médicaments   contenant comme substance ac- tive certains des sels en question ainsi que le mode de préparation de ces médicaments., 
La dose unitaire pour adultes est comprise entre 10 et   60   mg, de préférence entre 20 et 40 mg. 



    EXEMPLE   2.- 
 EMI4.1 
 Comprimes contenant 40 mg de chlorhydrate de b3.s-.-hysiroxy phny, j . cuino3,y.- .mGhan   Composition :    Un comprima   contient   
 EMI4.2 
 chlorhydrate de big-(4-hydroxyphênyl)- \quinolyl-2)-mêthane 40,0 mg -l.actose 11810 mg fécule de pommes de terre 50O mg polyvinylpyrrolidone 9,0 mg acide tartrique 1;0 mg stéarate de magnésium 2,0 mg 220,0 mg 
 EMI4.3 
 .El:09éd ..de.,.fabr;.9ation .- 
On granule, à travers un tamis de largeur de maille de   1,5   mm, le mélange constitué par l'ingrédient actif, le lactose et la fécule de pommes de terre, en ayant   reoours à   une solution éthylique à 15 % de   polyvinylpyrroli.     dons,   dans laquelle on a également dissous l'acide tartrique. 



    On   sèche 10 granulat à 45 C et on le fait pass er à nouveau par le tamis précité. On le mélange ensuite avec le stéarate de magnésium et on en fabrique des comprimés à la presse. 



  Poids d'un comprimé : 220 mg   Poinçon 9 mm .    



  EXEMPLE 3. - Suppositoires contenant 150 mg de chlorhydrate de bis-(4- 
 EMI4.4 
 hydroxyphônyl)-(quinolyl-2)-m'thane. 

 <Desc/Clms Page number 5> 

 
 EMI5.1 
 ,cor:pt>s11iion ; Un   suppositoire   contient 
 EMI5.2 
 Ch10rhydrate de bis-{lt-'bydrOX1phény.l)-(qui- nolyl-2)-mé'tba:ne 15D,0 3Bg 
 EMI5.3 
 
<tb> 5 <SEP> masse <SEP> pour <SEP> suppositoires <SEP> (par <SEP> exemple <SEP> celle
<tb> connue <SEP> sous <SEP> la <SEP> marque <SEP> Witepsol <SEP> W <SEP> 45) <SEP> 155D,0 <SEP> mg
<tb> 
<tb> 1700,0 <SEP> mg
<tb> 
   Procédé   de   fabrication )   
On fait   fondre   la sasse pour suppositoires à la   température   de 37 C.

   On y incorpore en agitant l'ingré- dient actif   finement     pulvériBé,   on refroidit jusqu'à 35 C et on   verse   la mass e fondue dans les mouler pour   supposi-   toires   préalablement   refroidis. 



   Poids   d'un-suppositoire   1,7   @.   



   EXEMPLE 4. - 
 EMI5.4 
 Suspension contenant dans N3. 20 mg de chloih5µ&W0e bis-(4-hydroxyphényl)-(quinolyl-2)-méthane Composition; 100 ml de suspension contiennent: 
 EMI5.5 
 Chlorhydrate de 3s- -ysiroxypny3,. 
 EMI5.6 
 
<tb> (quinolyl-2)-méthane <SEP> 0,4
<tb> 
<tb> 
<tb> aérosil <SEP> 3,0 <SEP> g
<tb> 
<tb> 
<tb> 
<tb> carboxyméthylçellulose <SEP> fortement <SEP> visqueuse <SEP> 0,5 <SEP> g
<tb> 
<tb> 
<tb> 
<tb> p-oxybenzoate <SEP> de <SEP> méthyle <SEP> 0,07 <SEP> g
<tb> 
<tb> 
<tb> 
<tb> p-oxybenzoate <SEP> de <SEP> propyle <SEP> 0,03 <SEP> g
<tb> 
<tb> 
<tb> 
<tb> esseane <SEP> de <SEP> cacao <SEP> 1,5 <SEP> g
<tb> 
<tb> 
<tb> 
<tb> glycérine <SEP> 5,0 <SEP> g
<tb> 
<tb> 
<tb> 
<tb> s <SEP> ucre <SEP> 32,0 <SEP> g
<tb> 
<tb> 
<tb> 
<tb> eau <SEP> distillée <SEP> 72,5 <SEP> g
<tb> 
<tb> 
<tb> 
<tb> 115.

   <SEP> 0 <SEP> @
<tb> 
 Procédé de .fabrication 
 EMI5.7 
 On dissout les esters de laolde p-.xybaoue dans l'eau distillée chauffée à 80 C, on y met en suspension   l'aérosil   et on ajoute le mélange de   carboxyméthylcellulose   et de sucre. Après refroidissement jusqu'à la température 

 <Desc/Clms Page number 6> 

 ambiante, on   est   en suspension dans la solution la substance active finement   pulvérisée.et   on ajoute ensuite la glycérine et l'essence de cacao. 



   5 ml de suspension contiennent 20 mg de chlor- hydrate de bis-(4-hydroxyphényl-(quinolyl-2)-méthane.



   <Desc / Clms Page number 1>
 
 EMI1.1
 



  Stable addition salts of bis. (4-hydroxyphny.- (quinolylJ-2) methane with acids
The invention relates to stable addition salts of bis- (4-hydroxyphenyl) - (quinolyl-2) -methane with acids.
 EMI1.2
 German Patent No. 0, $ 7,011 describes inter alia the manufacture of bia- (4 "hydroxyphenyl) - (quinolyl <2) -methane of the formula;
 EMI1.3
 by the reaction between quinolyl-1-aldehyde and phenol; this compound has a remarkable laxative effect and very low toxicity,

 <Desc / Clms Page number 2>

 
 EMI2.1
 However, it turned out that b.s- (4hYdroxyphëny.).



    (quinolyl-2) -methane, which when freshly prepared is a colorless substance, becomes colored on prolonged storage due to slow modification of the molecule. This coloration occurs rapidly during the treatment with polar solvents such as, for example, mixtures of ethanol and water of the kind which are applied, for example, for the granulation prior to the formation of tablets by compression, this which constitutes a serious drawback for the manufacture of pharmaceutical preparations.



   We have now discovered, in an unexpected way- that we can avoid these drawbacks, when
 EMI2.2
 converts bis- (4-hydroxyphenyl) - (quinolyl-2) -methane or
 EMI2.3
 in its addition salts with physiologically tolerable strong mineral / organic acids. In addition, these salts are distinguished by excellent gastric tolerance. As mineral acids, there may preferably be mentioned hydrochloric, hydrobromic, sulfuric and phosphoric adices,
 EMI2.4
 r3c4mms strong organic acids, methanesulfonic acids, p. to.uneau, fonâ.que and benzenesulfonic, The conversion of b. s.

   (... hYdraxynnnyx) - (quirolyl-2j methane in its addition salts with physiologically tolerable acids advantageously takes place in an inert solvent * The solvents mainly taken into account are, for example, ketones such as 'acetone, or alcohols such as, for example, methanol or ethanol,
 EMI2.5
 Salts of bis. (,. hydroxyphnyl) .. (quinel 1 ... 2 .. methane are distinguished by excellent tolerance and a remarkable laxative effect, Thus, bis- hydrochloride

 <Desc / Clms Page number 3>

 
 EMI3.1
 (4-hYdrïoxYPhênYl) - (quinolYI-2) -methane exerts its laxative effect on humans already at a dose of 30 mg.



   Stable pharmaceutical preparations such as tablets, suppositories and suspensions can be made from these salts. Since the
 EMI3.2
 bis - (@ - hydroXyphenyl) - (quinolyl-2) -methane salts Have a very good gastric tolerance, the coating of tablets containing these salts becomes unnecessary. The dosage for adults is between 30 and 250 mg.



   The examples below serve to illustrate the invention in more detail, EXAMPLE 1, Preparation of bis- (4-hydroxy- hydrochloride).
 EMI3.3
 phenyl) - (quinolyl-2) -methane, 40 g of bis- (Y-hydroxyphenylJ- (quinolyl-2) - methane are suspended in 200 ml of acetone. Hydrochloric gas is introduced into this mixture until saturation. , with stirring and cooling, the light yellow crystalline mass is filtered off and dried to give 39 g of PF hydrochloride, 205 C.
 EMI3.4
 



  By reacting bis- (4-hydroxyphenyl) - (quiolYl- 2) -methane in acetone or in ethanol with the corresponding acids, the salts below are obtained
 EMI3.5
 a) the acid sulfate Paf '. 238 * r, b) methane sulfonate P.F. 224 * 0 and) toluene sulfonate P.F, 136 0 d) benzenesulfonate P.F. 1) 8 C su hydrobromide, F, 21,800 acid phosphate Bzz. 22600

 <Desc / Clms Page number 4>

 
Below is given, by way of example, the composition of some medicaments containing as active substance some of the salts in question as well as the method of preparation of these medicaments.
The unit dose for adults is between 10 and 60 mg, preferably between 20 and 40 mg.



    EXAMPLE 2.-
 EMI4.1
 Tablets containing 40 mg of b3.s -.- hysiroxy phny hydrochloride, j. cuino3, y.- .mGhan Composition: One tablet contains
 EMI4.2
 big- (4-hydroxyphenyl) - \ quinolyl-2) -methane hydrochloride 40.0 mg -l.actose 11810 mg potato starch 50O mg polyvinylpyrrolidone 9.0 mg tartaric acid 1; 0 mg magnesium stearate 2, 0 mg 220.0 mg
 EMI4.3
 .El: 09ed ..of.,. Manufacture; .9ation .-
The mixture consisting of the active ingredient, lactose and potato starch is granulated, through a sieve with a mesh width of 1.5 mm, in addition to a 15% ethyl solution of polyvinylpyrroli. donations, in which tartaric acid has also been dissolved.



    The granulate is dried at 45 ° C. and again passed through the aforementioned sieve. It is then mixed with the magnesium stearate and compressed into a press.



  Weight of one tablet: 220 mg Hallmark 9 mm.



  EXAMPLE 3. - Suppositories containing 150 mg of bis- (4-
 EMI4.4
 hydroxyphenyl) - (quinolyl-2) -methane.

 <Desc / Clms Page number 5>

 
 EMI5.1
 , cor: pt> s11iion; One suppository contains
 EMI5.2
 Bis- {lt-'bydrOX1pheny.l) - (qui-nolyl-2) -mé'tba: ne 15D, 0.3Bg hydrochloride
 EMI5.3
 
<tb> 5 <SEP> mass <SEP> for <SEP> suppositories <SEP> (by <SEP> example <SEP> the one
<tb> known <SEP> under <SEP> the <SEP> brand <SEP> Witepsol <SEP> W <SEP> 45) <SEP> 155D, 0 <SEP> mg
<tb>
<tb> 1700.0 <SEP> mg
<tb>
   Manufacturing process )
The suppository bowl is melted at a temperature of 37 C.

   The finely pulverized active ingredient is stirred in, cooled to 35 ° C. and the molten mass is poured into the precooled suppository molds.



   Weight of one-suppository 1.7 @.



   EXAMPLE 4. -
 EMI5.4
 Suspension containing in N3. 20 mg of chloih5µ & W0e bis- (4-hydroxyphenyl) - (quinolyl-2) -methane Composition; 100 ml of suspension contains:
 EMI5.5
 3s- -ysiroxypny3 hydrochloride ,.
 EMI5.6
 
<tb> (quinolyl-2) -methane <SEP> 0.4
<tb>
<tb>
<tb> aerosil <SEP> 3.0 <SEP> g
<tb>
<tb>
<tb>
<tb> carboxymethylcellulose <SEP> highly <SEP> viscous <SEP> 0.5 <SEP> g
<tb>
<tb>
<tb>
<tb> p-oxybenzoate <SEP> of <SEP> methyl <SEP> 0.07 <SEP> g
<tb>
<tb>
<tb>
<tb> p-oxybenzoate <SEP> from <SEP> propyl <SEP> 0.03 <SEP> g
<tb>
<tb>
<tb>
<tb> esseane <SEP> of <SEP> cocoa <SEP> 1,5 <SEP> g
<tb>
<tb>
<tb>
<tb> glycerin <SEP> 5.0 <SEP> g
<tb>
<tb>
<tb>
<tb> s <SEP> ucre <SEP> 32.0 <SEP> g
<tb>
<tb>
<tb>
<tb> <SEP> distilled water <SEP> 72.5 <SEP> g
<tb>
<tb>
<tb>
<tb> 115.

   <SEP> 0 <SEP> @
<tb>
 Manufacturing process
 EMI5.7
 The esters of laolde p-.xybaoue are dissolved in distilled water heated to 80 ° C., the aerosil is suspended therein and the mixture of carboxymethylcellulose and sugar is added. After cooling to temperature

 <Desc / Clms Page number 6>

 ambient, the finely pulverized active substance is suspended in the solution, and the glycerin and cocoa oil are then added.



   5 ml of suspension contains 20 mg of bis- (4-hydroxyphenyl- (quinolyl-2) -methane hydrochloride.

 

Claims (1)

RESUME L'invention a pour objet ! EMI7.1 1) les sels d'addition stables du bia-(4hydroxyphényl).- (qqin91yl-1#-néthano aveq des acides physiologiquement gupportobles lesdits sel!9 ayant un pouvoir laxatif et présentant la formule : EMI7.2 dans laquelle X représente l'anion d'un acide minéral ou organique fort. EMI7.3 ABSTRACT The object of the invention is! EMI7.1 1) stable addition salts of bia- (4hydroxyphenyl) .- (qqin91yl-1 # -néthano aveq physiologically gupportable acids said salts! 9 having a laxative power and having the formula: EMI7.2 in which X represents the anion of a strong mineral or organic acid. EMI7.3 9) Le chlorhydrate de bis-(4"hYdroxyphënYl)"(qunolyl" )-.mothane # Lthydrogénoeultate de bis.(4bydroyphény)"(quinolrl. 9) Bis- (4 "hydroxyphenyl)" (qunolyl ") -. Mothane hydrochloride # Bis (4bydroypheny)" hydrogénoeultate (quinolrl. 2)-thane. 2) -thane. 4) Le méthanoeulfonate de bi"(4-hydroxyphényl}uinolyl- g)-méth4no, 5) Le tpluène"oulfonate de bia(4-hYdroxyphénYl)1quinoly 8)-B!éhane, 6) Le banzne-aulfonae de bia"'(4...hydrophênyl )-('1u:1no],y3,. 4) Bi "(4-hydroxyphenyl} uinolyl- g) -meth4no methanoeulfonate, 5) Bia (4-hydroxyphénYl) 1quinoly 8) -B! Ehane, 6) Bia-aulfonae tpluene" ' (4 ... hydrophenyl) - ('1u: 1no], y3 ,. 2r-métnaoe 7) Le bnomhydrate de b#s (y hydroxyph±nyl) (quinQlyl4 2 ) ""mêthQne , 8) La phosphate acide de bis-(4m hydroxyphényl(qu1nolyl" 1)-m4thane, 9) Lee preperetona pharma9eutiqoea contenant en tant que substance active un ou plusieurs des composa définis ci-dessus ainsi qu'un ou plusieurs adjuvante, supporta <Desc/Clms Page number 8> et/ou diluants pharmaceutiques solides ou liquides, non toxiques et physiologiquement supportables . 2r-methane 7) B # s (y hydroxyph ± nyl) (quinQlyl4 2) "" methQne hydrate, 8) Bis- (4m hydroxyphenyl (quinolyl "1) -m4thane acid phosphate, 9) Lee preperetona pharma9eutiqoea containing as active substance one or more of the compounds defined above as well as one or more adjuvant, supporta <Desc / Clms Page number 8> and / or solid or liquid pharmaceutical diluents, non-toxic and physiologically tolerable. 10) Les composés définis ci-dessus utilisés comme substance active dans des préparations pharmaceutiques, les doses posologiques unitaires pour adultes étant compri- ses dans le cas de l'administration par voie orale, entre 10 et 60 mg, de préférence entre 20 et 40 mg, et, dans le ces de l'administration par voie rectale, entre 20 et 150 mg. 10) The compounds defined above used as active substance in pharmaceutical preparations, the unit dosage doses for adults being included in the case of oral administration, between 10 and 60 mg, preferably between 20 and 40 mg, and, in the case of rectal administration, between 20 and 150 mg.
BE693874D 1967-02-09 1967-02-09 BE693874A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BE693874 1967-02-09

Publications (1)

Publication Number Publication Date
BE693874A true BE693874A (en) 1967-07-17

Family

ID=3850211

Family Applications (1)

Application Number Title Priority Date Filing Date
BE693874D BE693874A (en) 1967-02-09 1967-02-09

Country Status (1)

Country Link
BE (1) BE693874A (en)

Similar Documents

Publication Publication Date Title
JP2951402B2 (en) Anti-atherosclerotic aryl compounds
WO1995001333A1 (en) Acetamide derivatives and their use for modifying feeding behaviour modifiers
JPH0249294B2 (en)
US4147780A (en) α-Amino-phosphonous acids for inhibiting bacteria and yeast
US4304782A (en) Psychotropic deuterated derivatives of phenylhydantoin and pharmaceutical compositions comprising such derivatives
JPH04257587A (en) Codein salt of substituted carboxylic acid
FR2491467A1 (en) NOVEL LOWER N-ALKYL) -3-PHENOXY-1-AZETIDINECARBOXAMIDES HAVING IN PARTICULAR AN ACTIVITY ON THE CENTRAL NERVOUS SYSTEM, AND PROCESS FOR THEIR PREPARATION
EP0047536A2 (en) Substituted propylamines
EP0151072A2 (en) Derivatives of methylenediphosphonic acid, process for their preparation and antirheumatic pharmaceutical compositions containing them
FR2476071A1 (en) NOVEL 2-AMINO-3- (A-HYDROXYBENZYL) -PHENYLACETIC ACIDS AND THEIR ESTERS AND AMIDES, PARTICULARLY USEFUL AS ANTI-INFLAMMATORY AGENTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
CA1312333C (en) Strontium salt, its preparation process and the pharmaceutical compositions containing it
RO115519B1 (en) 1-arylcycloalkyl sulphides, sulphoxides and sulphones, process for preparing the same and pharmaceutical composition containing them
FR2465710A1 (en) NOVEL AMINO-2-BENZOYL-3-PHENYLACETAMIDES AND THEIR USEFUL CYCLIC HOMOLOGISTS AS MEDICAMENTS AND THERAPEUTIC COMPOSITIONS AND PHARMACEUTICAL FORMS CONTAINING SAME
BE693874A (en)
EP0115714A1 (en) Pharmaceutical composition with psychotropic dopaminergic action
CH449652A (en) Process for preparing new hydroxydiamines
FR2499981A1 (en) 2-AMINO-HALOGENOBENZOYL-3-METHYLPHENYLACETIC ACIDS AND THEIR USEFUL ESTERS AND SALTS AS ANTI-INFLAMMATORY AND ANALGESIC DRUGS
US3870792A (en) Certain dihydrophthalizines for treating hemorrhage and thrombosis
CH641775A5 (en) N- (1-METHYL 2-PYRROLIDINYL METHYL) 2,3-DIMETHOXY 5-METHYLSULFAMOYL BENZAMIDE AND DERIVATIVES THEREOF, PROCESS FOR PREPARING THE SAME AND COMPOSITION FOR THE CONTAINER.
CA1098524A (en) Process for the preparation of new derivatives of piperazincarbodithioic acid
FR2547821A1 (en) 2-PIPERAZINOPYRIMIDINE SALT, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US4218464A (en) 4- and 5-Substituted 2,3-dihydro-1H-isoindoles, pharmaceutical compositions and method of inhibiting phenylethanolamine N-methyltransferase
US3652582A (en) Adduct of 5 5-dimethylhydantoin with chloral hydrate and its preparation
EP0179076B1 (en) Sulphureous hydantoin derivatives and pharmaceutical compositions containing them
FR2536071A1 (en) 2-PIPERAZINOPYRIMIDINE ACID SALTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME